BVF Inc. IL Sells 717,000 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

BVF Inc. IL trimmed its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 15.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,944,194 shares of the company's stock after selling 717,000 shares during the quarter. Tyra Biosciences makes up about 1.9% of BVF Inc. IL's portfolio, making the stock its 12th largest holding. BVF Inc. IL owned about 7.79% of Tyra Biosciences worth $54,824,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also added to or reduced their stakes in TYRA. RA Capital Management L.P. lifted its holdings in shares of Tyra Biosciences by 2.1% during the fourth quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock worth $147,858,000 after purchasing an additional 220,681 shares during the period. Alta Partners Management Company L.P. acquired a new position in Tyra Biosciences during the 4th quarter worth about $56,716,000. Boxer Capital Management LLC bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at about $28,185,000. JPMorgan Chase & Co. increased its stake in shares of Tyra Biosciences by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after buying an additional 3,896 shares during the period. Finally, Pictet Asset Management Holding SA acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $4,921,000. Institutional investors own 84.14% of the company's stock.

Tyra Biosciences Stock Performance

Shares of TYRA stock traded down $0.18 during trading hours on Friday, hitting $9.89. 281,434 shares of the company were exchanged, compared to its average volume of 257,995. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The company has a 50 day simple moving average of $9.66 and a two-hundred day simple moving average of $13.43. The firm has a market cap of $525.06 million, a P/E ratio of -6.14 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. As a group, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Wedbush restated an "outperform" rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Friday, March 28th. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, March 31st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $30.83.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.